10th International Pulmonary Hypertension Conference: Scientific Sessions

简介(申请人提供)：肺动脉高压协会(PHA)成立于1990年，是一个为受肺动脉高压影响的患者及其家属服务的组织。由于其创始人了解让医疗专业人员和研究人员参与PHA活动的重要性，医学界成员在PHA于1994年举行的第一次国际PH会议以及此后的每一次会议上都发挥了积极的作用。从2004年的会议开始，PHA在国际PH会议上安排了一整天的科学会议，汇集了PH专家，深入探讨当前科学感兴趣的话题。第十届国际PH大会和科学会议将于2012年6月21-24日在佛罗里达州奥兰多举行。即将举行的科学会议的主题是肺动脉高压(PH)的遗传学。科学会议于6月21日晚上开始，6月22日全天持续。2012年科学会议的具体目标是：1)描述公认为具有可遗传的肺动脉高压病因的疾病及其相关基因；2)描述骨形态发生蛋白受体2(BMPR2)在PAH病理生物学中的作用及其作为潜在治疗靶点的途径；3)讨论表观遗传修饰在PH病理生物学中的作用。科学会议将包括一个开幕式，讨论全球范围的肺动脉高压及其在发展中国家被遗忘的影响。“为期一天的会议将包括五个关于PH遗传学各个方面的主旨演讲，四个从海报会议中挑选出来的摘要演讲，以及一个预期为100张海报的海报会议。这些海报还将在整个会议期间供人查看。预计将有大约400名医疗专业人员和研究人员参加科学会议。为了保持演讲的长期价值，这些演讲将被记录下来，在科学会议结束后提供给与会者，并张贴在公共卫生署的在线大学(http://www.PHAonlineuniv.org/))上，以供所有感兴趣的各方进行持续教育。公共卫生相关性：第十届国际PH会议和科学会议将讨论与肺动脉高压有关的遗传机制。尽管FDA现在批准了九种治疗PH的方法，许多患者的寿命也更长了，但PH仍然是一种晚期疾病，患者的生活质量往往很差。这次会议将把PH科学家、临床医生和其他心血管科学家聚集在一起，通过分享专业知识和研究来促进对这种疾病的了解。

DESCRIPTION (provided by applicant): The Pulmonary Hypertension Association (PHA) came into being in 1990 as an organization for patients and family members affected by pulmonary hypertension. Because its founders understood the importance of involving medical professionals and researchers in the activities of PHA, members of the medical community played an active role in PHA's first International PH Conference which took place in 1994 and in every Conference since. Beginning with the Conference in 2004, PHA has included a full-day of Scientific Sessions in the International PH Conference, bringing together PH experts to delve deeply into a topic of current scientific interest. The 10th International PH Conference and Scientific Sessions will be held in Orlando, Florida, on June 21-24, 2012. The theme of the upcoming Scientific Sessions is Genetics of Pulmonary Hypertension (PH).¿ The Scientific Sessions begin on the evening of June 21 and continue throughout the day on June 22. Specific objectives of the 2012 Scientific Sessions are to: 1) describe the diseases recognized as having a heritable etiology of Pulmonary Hypertension and the genes involved; 2) describe the role of bone morphogenic protein receptor 2 (BMPR2) in the pathobiology of PAH and its pathway as a potential therapeutic target; and 3) discuss the contribution of epigenetic modifications in the pathobiology of PH. The Scientific Sessions will include an opening session to discuss the Global Spectrum of Pulmonary Hypertension and its Forgotten Impact in the Developing World." The day-long session will feature five keynote presentations on various aspects of the genetics of PH, four selected abstract presentations from the poster session, and a poster session of an anticipated 100 posters. The posters will also be available for viewing throughout the conference. It is expected that approximately 400 medical professionals and researchers will attend the Scientific Sessions. To preserve the long-term value of the presentations, they will be recorded and made available to participants following the Scientific Sessions and posted on PHA's Online University (http://www.PHAonlineuniv.org/) for the ongoing education of all interested parties. PUBLIC HEALTH RELEVANCE: The 10th International PH Conference and Scientific Sessions will address genetic mechanisms related to pulmonary hypertension. Although there are now nine FDA approved treatments for PH and many patients are living longer, PH remains a terminal disease and patients¿ quality of life is often poor. This meeting will bring PH scientists, clinicians and other cardiovascular scientists together to advance understanding of this disease through sharing expertise and research.